Shingles

GlaxoSmithKline’s recombinant zoster vaccine (adjuvanted) (Shingrix) has been approved in Canada for the prevention of herpes zoster (shingles) in people aged 50 years and older. “The vaccine combines an antigen, glycoprotein E, and an adjuvant system, AS01B, intended to generate a strong and long-lasting immune response that can help overcome the decline in immunity as […]